History

Neocutis' story began with a simple observation: prenatal surgery can be done so that the baby rarely presents scar formation after birth. What allows the enormous wound healing capacity of fetal skin? And, how can one use these capacities to cure different types of skin disorders?

The “Laboratoire de Médecine Foetale” at the Medical School of the University Hospital of Lausanne has worked extensively with fetal cells since 1995 and resulted in several patent applications.

During the later part of 2002, experienced business people joined the team of physicians and biologists working at Lausanne University to found Neocutis.

The founders then spent the first 18 months protecting the intellectual property of their proprietary technology defining a business strategy, setting up a business plan and hiring the pioneers in order to establish the skin cell bank.

In July 2004, a group of financial investors led by Venture Incubator closed a first financing round. Investors are a mix of Swiss Venture Capital funds and business angels.

This financing enabled Neocutis to launch its first product in the US market, "Neocutis Bio-restorative Skin Cream"; a cosmeceutical sold through physicians. In parallel, Neocutis continues the process of developing a a novel topical drug.

In the second half of 2004, Neocutis Inc. was founded and headquartered in San Francisco. Neocutis Inc. heads all of the commercial activites.